SERES
13.1.2023 14:31:38 CET | Business Wire | Press release
For 36 years, SERES, a subsidiary of the eponymous Chinese group, has positioned itself as a premium smart e-vehicle brand. After five years of development and testing, the company is officially launching the cutting-edge, high-performing, high-tech SERES 5 in Europe. Available in three models (Standard version 2WD, Premium version 4WD, Flagship version 4WD) the SERES 5 is a sporty, premium e-SUV that blazes a new trail by combining the best of everything: design, smart driving, power, range and comfort. From January 14 to 22, visitors to the Brussels Motor Show will get an exclusive sneak peek at the premium sport E-SUV before it goes on sale in March.
Natural Aesthetics of Life
Many people sat up and took notice when the SERES 5 concept was unveiled in Silicon Valley. In particular, its design caught their eye as SERES5 is inspired by nature with flexibility, purity and vitality. Special attention was paid to the nature-inspired aesthetics (Σ front face, willow-inspired window, Belt line mimics dolphin’s leaping). The roofline continuously and uninterruptedly descends to the trunk, giving the vehicle an ultra-low wind resistance, making it more dynamic and more energy efficient 1. The SERES 5 is available in 8 exterior colours and 5 interior ones that can be combined as desired.
Zero to 100 km/h in 3.7 seconds and a range up to 530 km
Behind its premium design lies an amazing driving experience enhanced by a performance worthy of the market’s top models. The SERES 5 accelerates from 0 to 100 km/h in 3.7 seconds thanks to its front and rear motor peak power (430KW) and peak torque 960N.m.
To control acceleration and stabilize the vehicle, the chassis is mainly made of a strong, lightweight aluminium alloy. For a premium driving experience, a dual ball joint front double-wishbone front suspension enhances anti-roll performance and a multi-link trapezoidal arm type rear independent suspension improves stability.
The SERES 5 boasts an outstanding range. Its 80kWh lithium iron phosphate and 90 kWh semi solid state high performance batteries offer a significant power supply and high energy efficiency. Thus, on a single charge the 2WD model can travel 500 km WLTP and the 4WD can cover 530 km WLTP. They are compatible with 95% of the charging systems available in Europe. Moreover, SERES 5 includes a smart fast charging system: a quick recharge to shorten the waiting time on the way and, on camping ground, a V2L function can provide power to many travel appliances such as induction cookers and coffee makers, while the V2V function can also help charge other people’s EV’s in emergency.
The SUV is also equipped with an industry leading permanent magnet motor: a little technological gem.
A safe, unparalleled driving experience
The SERES 5 also stands out for its 18 assisted-driving features, +300 smart voice assistants (8 active service reminders, 14 telephone operations, 17 navigation operations, 35 multimedia operations, ...), 3 smart scenarios (rest mode, temporary stop mode, camping mode) and over 20 "Smart Car Ecology" devices (on-line map, On-line music, car game, DAB digital radio).
As a safety feature, voice commands let the driver control everything from air conditioning to music while keeping both hands on the wheel and eyes on the road. The SERES 5 also has LFP batteries and, for the first time, a semi-solid battery as standard equipment that has undergone around 100 tests, with a long service life (100,000 km without degradation) and high peak power (430 KW). What’s more, the SERES 5 benefits from a five-level safety management system and has travelled the equivalent of 5.000.000 km in extreme conditions (cold, heat, high altitudes, etc.) to ensure optimal use. To provide the best of breed, the brand has also gathered a global supply chain system of experts (Astemo, Longhorn, Bosch, Valeo, Pirelli, BASF, …) around its SERES 5.
Finally in order to provide worry-free travel to its customers, SERES offers two outstanding warrantees: a 8 years (160.000 km) warranty for the battery, electric motor and electric control system and a 4 years (100.000 km) warranty for the vehicle. Besides, SERES 5 drivers will benefit from a 24hours emergency rescue road service, as well as online and offline customer services to all SERES valued customer.
Custom-made comfort for stress-free driving
SERES takes pride in putting technology to work for drivers and passengers with intelligent interiors geared to their needs. For example, instead of displaying all the features on a single central screen, three of them are arrayed around the driver to make the important messages visible while ensuring that the view is clear at every angle (HUD, 15.6” large central control screen, 12.3” LCD dashboard).
For a comfortable ride, the front seat can be adjusted in 12 different ways and is equipped with various settings such as ventilation, heating, memory, massage ... The SERES 5 also has two 40W wireless fast chargers (front and rear) to meet a wide variety of needs. The optional 85-inch deluxe panoramic skyline (field ratio 97.7%) offers a wide range of view while giving a unique impression of space. Lastly, new soundproofing and heat insulation materials keep the inside very quiet whatever the speed.
At the press conference, Mr. John Zhang, the chairman and founder of SERES Group emphasized that “In making SERES into a high-end, intelligent new energy vehicle brand, starting 2016, the group had consistently invested over 10% of its total revenue each year in Intelligent EV technologies. We have built industry 4.0 standard Intelligent factories, have developed and launched high-performance battery and range of other intelligent EV related products. Today these technologies are not only leading the sector in China but are considered to be on an advanced level on a global scale.”
The SERES 5 will be available from the brand's European sales network in March
Dimensions: 4710 x 1930 x 1620 mm
Standard version 2WD: from €63,9002
Premium version 4WD: from €67,900
Flagship version 4WD: from €74,900
1278 Cd drag coefficient
2 indicative prices for the German market
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230113005191/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom